Acute and chronic lithium treatment increases Wnt/β-catenin transcripts in cortical and hippocampal tissue at therapeutic concentrations in mice

Paula, Vanessa de; Santos, Carla C. C. dos; Luque, Maria Carolina Aquino; Ali, Taccyana M.; Kalil, Jorge; Forlenza, Orestes Vicente; Cunha‐Neto, Edécio

doi:10.1007/s11011-020-00638-8

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as depicted in Figure 1. Wnt signaling activity is a pro-differentiating force in normal muscle [86,87] as well as in rhabdomyosarcoma [7,88,89]. Wnt agonists decreased proliferation and promoted differentiation in a-rhabdomyosarcoma cells [90].…”

Section: Lithiummentioning

confidence: 99%

SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin

Kast,

Zaghloul,

Sardi

et al. 2023

Preprint

View full text Add to dashboard Cite

Rhabdomyosarcoma is a cancer arising from arrested myogenic differentiation, seen mainly in children or adolescents. Metastatic rhabdomyosarcoma is often fatal even with aggressive cytotoxic chemotherapies, surgery, and irradiation. SALIQ is an acronym for a multidrug augmentation regimen designed as an adjunct to current rhabdomyosarcoma chemotherapies. SALIQ uses five common non-oncology drugs, repurposed from general medicine use, to promote malignant clone maturation and inhibit rhabdomyosarcoma growth. The five drugs are: the cholesterol lowering drug simvastatin, the acne medicine tretinoin (ATRA), the psychiatric drug lithium carbonate, the antifungal drug itraconazole, and the food supplement quercetin. All five drugs are in common use for non-cancer conditions, are cheap, have an eminently safe side effect profile, and all five have preclinical evidence and good rationale for inhibiting rhabdomyosarcoma growth.

show abstract